A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, phase 1b study designed to evaluate
safety, tolerability, PK, and preliminary efficacy of APL-1401 in patients with moderately to
severely active UC. This study comprises 3 periods including screening period (D-28~D-1),
treatment period (D1-D28), and safety follow-up period(D29-D58).